Tergene, is a biotech company promoted by a
scientist turned entrepreneur with a vision of providing quality
Tergene is developing bio-conjugate platform technologies for
novel vaccines and antibody drug conjugates. A basket of
vaccines against bacterial pneumonia is under various stages of
Tergene's upcoming GMP facility at Hyderabad, India is expected to be operational by the end of 2014. The facility
would be used for the manufacture of vaccines, biopharmaceuticals
Vision & Mission
Vision is to deliver the best
quality, cost-effective biologics to all categories of people.
is to improve the quality of life thus
creating a healthier world.
"Mission - Vaccine to fight pneumonia deaths" - Biospectrum
magazine, Nov 2011.
Tergene offers GLP
grade Diphtheria toxin CRM 197 as lyophilized powder. CRM 197
is used as carrier protein in the development of conjugate
vaccines. For further information contact
Pneumococcal capsular polysaccharides of various serotypes are
available as lyophilized powder. For further information contact